Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?
Which drug combinations are right? Where does the balance between side effects and adherence lie?
These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.
Associate Professor of Medicine, Division of Allergy and Infectious Diseases
University of Washington
Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: October 11, 2022
Expiration date: October 10, 2024